COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges

Diabetes Metab Syndr. Mar-Apr 2021;15(2):505-508. doi: 10.1016/j.dsx.2021.02.026. Epub 2021 Feb 25.

Abstract

Background and aims: To summarize the available evidence on the use COVID-19 vaccines in patients with diabetes mellitus.

Methods: We performed a thorough literature search with regard to COVID-19 vaccines in patients with type 1 and type 2 diabetes mellitus.

Results: The novel coronavirus disease (COVID-19) tends to portend a poor prognosis in patients with diabetes mellitus (DM). Primary prevention remains the mainstay for mitigating the risks associated with COVID-19 in patients with DM. A significant step in primary prevention is timely vaccination. Routine vaccination against pneumococcal pneumonia, influenza, and hepatitis B is recommended in patients with DM with good efficacy and reasonable safety profile. With clinical data supporting a robust neutralizing antibody response in COVID-19 patients with DM, vaccination in individuals with DM is justified. In fact, as the burden of the disease is borne by people with DM, COVID-19 vaccination should be prioritized in individuals with DM. Multiple unresolved issues with regard to preferred vaccine type, vaccine efficacy and durability, frequency of administration, vaccination in children (<18 years) and pregnant/lactating women however remain, and need to be addressed through future research.

Conclusions: Patients with type 1 and type 2 diabetes mellitus are at a high risk of poor prognosis with COVID-19 and vaccination should be prioritized in them. However, many unresolved issues with regard to COVID-19 vaccination need to be addressed through future research.

Keywords: COVID-19; Diabetes mellitus; Vaccines.

Publication types

  • Review

MeSH terms

  • Antibodies, Neutralizing / immunology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / therapeutic use*
  • Diabetes Mellitus, Type 1*
  • Diabetes Mellitus, Type 2*
  • Humans
  • Risk Factors
  • SARS-CoV-2

Substances

  • Antibodies, Neutralizing
  • COVID-19 Vaccines
  • recombinant SARS-CoV-2 vaccine NVX-cov2373
  • ChAdOx1 COVID-19 vaccine
  • mRNA-1273 vaccine
  • Ad26.COV2.S vaccine
  • BNT162 vaccine